# Payers tend not to cover weight loss medications
Since GLP-1 RAs are primarily glucose-lowering medications, the benefits of selecting these agents should be weighed against the benefits of alternative diabetes control options
We went through intake and reached the payment screen at all 21 clinics we ordered from, then compared the number we were charged against the number we were shown
| doi:10.1016/j.bbamcr.2016.01.023 Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K, Olyaeemanesh A.: The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials
Solitary gastric melanotic schwannoma: sonographic findings
Three drugs are available, and many people respond to none of them